Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

New Liquid Ready-to-use Tumour Marker Control available now from Randox

Published: Thursday, November 22, 2012
Last Updated: Thursday, November 22, 2012
Bookmark and Share
The new Randox Acusera multi-analyte Liquid Tumour Marker Control covers a total of 15 commonly tested and esoteric cancer antigens and tumour markers.

The inclusion of assayed, instrument specific target values enables laboratories to effectively monitor both accuracy and precision.

The Liquid Tumour Marker Control includes AFP (Alpha-fetoprotein), Beta-2- Microglobulin, CA15-3,3xVials01---New-Randox-TM-c.gif CA19-9, CA27-29, CA72-4, CA125, CEA (Carcinoembryonic Antigen), Cyfra 21-1, Ferritin, hCG (Human Chorionic Gonadotropin), NSE (Neuron-specific Enolase), PSA Free (Prostate Specific Antigen Free), PSA Total (Prostate Specific Antigen Total) and Thyroglobulin.

The liquid ready-to-use format is highly convenient for laboratory staff to use requiring no preparation. Furthermore the material can be easily shipped and stored at +2-8oC.  Liquid stable controls not only eliminate the need for reconstitution but reduce the amount of human handling necessary. The user friendly 6 x 3ml pack size and open vial stability of 30 days at +2-8oC for all analytes listed significantly helps to minimise waste and keep running costs low.

Like all Randox immunoassay controls the serum is 100% human in origin providing a matrix similar to the patient sample but also reducing antibody cross reactivity and the possibility of control values shifting when reagent batch is changed. Three distinct levels of control are available with all analytes including PSA present at desirable levels.  Clinically relevant PSA levels ensure the ratio of free to bound PSA is typical of that found in cancer patients.

As a true third party control laboratories can use the Acusera liquid tumour marker control to independently assess analytical performance.  Fully assayed, instrument specific target values and ranges are provided for many common clinical chemistry and immunoassay systems.

For optimum performance and advanced analytical capabilities use in combination with Acusera 24.7 Live Online, an inter-laboratory data management programme designed to monitor analytical performance, interpret QC results and improve the effectiveness of quality control. With Acusera 24.7 users benefit from online access anytime, peer group data generated from thousands of laboratories every 24 hours, fully interactive charts and reports and automatic import of QC data direct from your LIMs or instrument via Acusera 24.7 Connect.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos